Effectiveness of Contingency Management in the Treatment of Crack Addiction in Brazil

NCT ID: NCT03345394

Last Updated: 2021-04-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-01

Study Completion Date

2020-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Crack addiction has become a severe public health problem in Brazil. Crack users present elevated prevalence rates of psychiatric comorbidities, sexual transmitted infections and unemployment with high probability of living or have lived in the streets, history of incarceration and engagement in illegal activities. For the last 20 years a treatment called Contingency Management (CM) have achieved the best results regarding reduction of substance use, promotion of abstinence, treatment attendance and retention in treatment. The first CM study conducted in Brazil advocates for the efficacy of CM on all of these outcomes, suggesting that CM can be effective in a Brazilian population of crack users.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to evaluate the effectiveness of Contingency Management (CM) for crack users living in the "Crackland" region. To achieve this goal, regular treatment staff from Unidade Recomeço Helvétia treatment service will be capacitated in CM to latter-on apply the CM intervention in their respective services. The design will be a single-blind randomized clinical trial composed of a sample of 100 subjects with current diagnose for crack/cocaine dependence. Participants allocated to the control condition will receive 12 weeks of the usual care treatment provided by these two treatment facilities. Participants allocated to the experimental condition will receive the exact same treatment as control participants associated with CM. CM procedure will occur 2 timer per week (every Monday and Thursday or Tuesday and Friday). Primary outcomes are: (1)retention in treatment; (2) reduction of crack use; (3) promotion of continuous crack cocaine abstinence. Secondary findings are reduction on psychiatric symptomatology. The investigator hypothesis is that participants in the CM condition will have a better treatment response in all studied outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Substance Use Disorders Contingency Management Addiction, Cocaine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Single-blind randomized controlled trial
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators
researchers had no contact with participants during the 12 week trial

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard Treatment

12 weeks of standard treatment offered by Unidade Recomeço Helvétia treatment program

Group Type ACTIVE_COMPARATOR

Standard treatment

Intervention Type BEHAVIORAL

Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program

Contingency Management

12 weeks of standard treatment offered at Unidade Recomeço Helvétia treatment program associated with Contingency Management

Group Type EXPERIMENTAL

Contingency Management

Intervention Type BEHAVIORAL

Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Contingency Management

Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples

Intervention Type BEHAVIORAL

Standard treatment

Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DSM-V diagnose for crack cocaine use disorder

Exclusion Criteria

* being under 18 years old
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Washington State University

OTHER

Sponsor Role collaborator

Federal University of São Paulo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

André de Queiroz Constantino Miguel

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andre M de Queiroz Constantino Miguel, PhD

Role: PRINCIPAL_INVESTIGATOR

Federal University of São Paulo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Unidade Recomeço Helvétia

São Paulo, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FAPESP 2017/05371-8

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Behavioral Effects of Drugs (Inpatient): 38
NCT03954938 TERMINATED EARLY_PHASE1
Cocaine Use Reduction and Health
NCT03224546 COMPLETED NA